Payment overview · 2025
General Payments
$488.97
5 reported records · 3 companies
Healthcare provider profile · identity verified
Roset Samuel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAS CRUCES, NM · NPI 1073590162
Verified facts
What the public records show
CMS Open Payments records show Roset Samuel, M.D. received $488.97 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.27 | 47.1% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $145.82 | 29.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.88 | 23.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $488.97 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $145.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $117.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $112.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 797 | 106 |
| Oxycodone Hcl | Oxycodone Hcl | 450 | 31 |
| Alprazolam | Alprazolam | 408 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 101 |
| Lisinopril | Lisinopril | 395 | 115 |
| Gabapentin | Gabapentin | 366 | 81 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 366 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 339 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 85 |
| Furosemide | Furosemide | 259 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 56 |
| Metformin Hcl | Metformin Hcl | 222 | 80 |
| Losartan Potassium | Losartan Potassium | 220 | 75 |
| Omeprazole | Omeprazole | 155 | 60 |
| Ibuprofen | Ibuprofen | 150 | 41 |
| Simvastatin | Simvastatin | 148 | 40 |
| Potassium Chloride | Potassium Chloride | 143 | 52 |
| Tramadol Hcl | Tramadol Hcl | 137 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 46 |
| Prednisone | Prednisone | 123 | 78 |
| Mounjaro | Tirzepatide | 120 | 21 |
| Pregabalin | Pregabalin | 114 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 36 |
| Lorazepam | Lorazepam | 106 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 26 |
| Eliquis | Apixaban | 99 | 30 |
| Famotidine | Famotidine | 99 | 35 |
| Azithromycin | Azithromycin | 97 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 32 |
| Sertraline Hcl | Sertraline Hcl | 94 | 27 |
| Trazodone Hcl | Trazodone Hcl | 91 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 30 |
| Clonazepam | Clonazepam | 85 | 13 |
| Januvia | Sitagliptin Phosphate | 83 | 18 |
| Levofloxacin | Levofloxacin | 80 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 30 |
| Celecoxib | Celecoxib | 79 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Ozempic | Semaglutide | 76 | 20 |
| Xarelto | Rivaroxaban | 76 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Montelukast Sodium | Montelukast Sodium | 64 | 15 |
| Prolia | Denosumab | 61 | 44 |
| Levetiracetam | Levetiracetam | 59 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Bupropion Xl | Bupropion Hcl | 54 | 15 |
| Spironolactone | Spironolactone | 54 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 43 |
| Donepezil Hcl | Donepezil Hcl | 51 | 18 |
| Meclizine Hcl | Meclizine Hcl | 51 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 15 |
| Glipizide | Glipizide | 47 | 12 |
| Allopurinol | Allopurinol | 44 | 14 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Lidocaine | Lidocaine | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 25 |
| Naproxen | Naproxen | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Carvedilol | Carvedilol | 39 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 21 |
| Glipizide Er | Glipizide | 38 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 15 |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Nystatin | Nystatin | 32 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 24 |
| Fentanyl | Fentanyl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Ofloxacin | Ofloxacin | 28 | 21 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Gemfibrozil | Gemfibrozil | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 16 |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 13 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Linezolid | Linezolid | 19 | 13 |
| Torsemide | Torsemide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 14 |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $488.97 · 5 records | Novo Nordisk Inc | AIRSUPRA, Ozempic, Senza, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error